We determined the molecular basis of cystathionine 0-synthase (CBS) deficiency In three siblings with pyridoxlne responsive homocystinurla using a significantly improved mutation screening method in bacteria. The phenotyplc expression of the siblings differed even though their CBS genotypes were identical. The paternal allele contained a linked pair of mutations, C233G and G^C, corresponding to P78R and K102N in the polypeptide chain. Together, these Inactivated the enzyme; however, expressed separately, they reduced activity by about one half. The single maternal mutation G 715 A (E239K) effectively abolished CBS activity. Subunlts of CBS were absent from patient fibroblast extracts; however, E.coll, transformed with plasmids containing patient CBS cDNA, expressed the subunlts, although in reduced amounts. The mother, an obligate heterozygote, was free from all signs of homocystinuria; nonetheless, extracts of her fibroblasts were devoid of CBS protein and activity. We conclude that fibroblast levels of CBS are only partially effective as prognosticators of disease severity and that It is important to test the In vivo response to vitamin B 6 in all cases of homocystinuria, Including those In which the mutations lead to the absence of the enzyme in cultured fibroblasts.
INTRODUCTION
A major focus of this laboratory has been the elucidation of the molecular genetics and biochemistry of cystathionine /3-synthase (EC 4.2.1.22; CBS), both in normal and abnormal states. This enzyme, a homotetramer of 63 kd subunits, catalyzes the formation of cystathionine from serine and homocysteine; patients who are homozygous for CBS deficiency excrete homocysteine in their urine (homocystinuria). While there are other factors which precipitate homocystinuria, CBS deficiency is the leading cause of this disease in humans (1) .
Homocystinuria in about 50% of patients responds to pharmacological doses of pyridoxine (Bg) (1, 2) , the precursor of pyridoxal 5'-phosphate (PLP). Indeed, we demonstrated the presence of PLP in pure human CBS (3) . If the affinity of the enzyme for PLP is reduced by a mutation, Bg treatment may enhance apoenzyme conjugation with PLP in vivo (4) .
We previously identified a mildly affected patient with no detectable CBS subunits in his cultured fibroblasts, yet who clinically responded to B 6 therapy (5, 6) . In the present study we describe three more pyridoxine responsive patients, a brother and two sisters, who respond in vivo to Bg therapy but have neither detectable activity nor CBS protein in their fibroblasts.
We examined the genetic basis of CBS deficiency in this interesting family comprising the mother and the three homocystinuric siblings. The two sisters exhibited classical clinical manifestations of homocystinuria while the brother was almost entirely free of disease. The mother, an obligate heterozygote, was free of homocystinuria, despite the absolute absence of fibroblast CBS activity. These observations led us to characterize both parental CBS alleles to attempt to provide a molecular basis for their condition.
We now report a single mutation of the maternal allele, together with a pair of mutations of the paternal allele, which inactivate the enzyme in the offspring. These mutations were localized by a significant improvement of our previously described bacterial expression method (6) . We also demonstrate, at the molecular level, that the mother is heterozygous for CBS deficiency, although her cultured fibroblasts are apparently devoid of the enzyme. Taken together, the results obtained for this family indicate that significant biological variability exists in the clinical signs of CBS deficiency, and that vitamin B 6 therapy should be tried even in the absence of detectable fibroblast CBS.
RESULTS

Patients: different clinical courses in three homocystinuric siblings
The three homocystinuric individuals of a sibship of seven were chosen for detailed study. Clinical studies of these patients were described previously (7) . Cell line numbers in this paper correlate with the previous designations (7) Figure 1 . CBS expression system in E.coli. Inactivating deletions were created in the 'wild-type' human CBS expression vector (top) by the manipulations indicated. The exon 12 deletion indicated was derived from a naturally occurring mutation. Separate expression cartridges were subsequently prepared by digesting the resulting vectors (middle) as indicated: NcoVXmal for the vector NX; Bpu 11021 BstXl, BB; BstXl/Kpnl, BK. Hybrid constructs (bottom) were prepared by inserting die corresponding segment from PCR-amplified patient cDNA. After transforming E.coli (DH5aF'IQ, Life Technologies, Grand Island,NY) with these constructions, individual clones were tested for CBS activity as described in Materials and Methods.
remaining four siblings were free of signs of homocystinuria, and were presumed to be heterozygous for CBS deficiency or normal. Their mother (3009) was clinically and biochemically healthy, except for macrocytosis of unknown origin. The father was not available for the study.
These patients were chosen for molecular analysis because of the remarkable differences in the severity of their clinical disease. Two sisters (1874, 1875) exhibited many features of the classical homocystinuric phenotype. Homocystinuria was first diagnosed in the younger sister (1875) when she was examined for developmental delay at thirteen months. She later developed severe mental retardation and suffered from seizures. At fourteen years of age, she underwent surgical intervention for scoliosis. Post-operatively she suffered popliteal vein thrombosis. Other skeletal involvements included osteoporosis of the spine and germ valgum. She was myopic but without lens dislocation. Her face was long and narrow and her oral features included a high arched palate and crowded teeth. She died of respiratory failure and cardiac arrest at 22, most likely from overuse of an antiasthmatic medication.
Homocystinuria was diagnosed in the older sister, 1874, at five years of age. She was severely mentally retarded but never developed seizures. Whereas her spine was normal, her long bones were osteoporotic. Following the initial diagnosis, she was found to have mild kyphosis of the upper thoracic spine, mild sternal depression, marked genu valgum and arachnodactyly. She was myopic, but, unlike her sister, exhibited bilateral lens dislocation. Recurrent malar flush was prominent when she was first diagnosed. She also had a long and thin face with high arched palate and malocclusion. She had mild mitral valve prolapse.
In contrast to his two female sibs, the eldest brother (1873) had none of the physical features associated with CBS deficiency. Furthermore, he had no symptoms of the disease apart from a single episode at age 30 of deep vein thrombosis of the left leg from which he recovered uneventfully. There have been no further clinical sequelae related to his homocystinuria to his present age, 37.
Determination of CBS activity in cultured fibroblasts
One unit of CBS activity catalyzes the formation of one nmol of cystathionine in one hour at 37°C. The CBS assay is capable of detecting 0.25% of control activity (8) . Fibroblast extracts from all three siblings were devoid of CBS activity, in the presence and absence of PLP. Surprisingly, maternal CBS activity was 0.79 U/mg protein which is in the affected patient range (8) . A repeated skin biopsy gave the same result. This is an exceptionally low value for an obligate heterozygote. Most heterozygotes have activities well above the patients' range (unpublished results).
Screening for CBS cDNA mutations
To identify the mutations in the CBS gene in these patients, we modified our previously described (6) bacteria expression system for CBS to increase its accuracy. To localize disease-causing mutations on the basis of their effect on CBS function, three different segments (NX, BB and BK) from patient's CBS cDNA were substituted in the corresponding 'wild type' CBS sequence already subcloned in expression plasmids. Plasmids containing each segment were used to transform separate E.coli cultures. Absence of CBS activity following expression suggested the presence of one or more inactivating mutations in the tested segment. Incomplete digestion of the cartridge prior to cloning increased the number of transformed bacteria expressing active CBS activity because the parent plasmid consisted of the normal sequence. To surmount this difficulty, we deleted portions of the respective test segments, yielding three separate vectors. A naturally occurring deletion of exon 12 (6) was introduced in the BK fragment whereas the other deletions were created by specific restriction enzyme digestions (See Fig.  1 ). These deletions ensured that active CBS could only arise from intact, nonmutated segments from the patient cDNA samples. Prior to expression the plasmids could quickly be screened by PCR and electrophoresis to determine that the short segment originally present had been replaced by the longer segment originating from the patient sample. These modifications greatly improved the efficacy of the original screening method.
CBS expression in E.coli
We expressed eight clones from cell strains 1873 and 1874 containing the authentic NX cDNA substitution, eight clones with the BB segment from 1873 and 1875, and 5 BK clones for each sibling. Fifteen clones from the mother's full-length cDNA were expressed (Table 1) as well as 18 segmental clones (6 clones for each segment). More than half of the NX clones from both patients (1873 and 1874) were devoid of CBS activity, indicating the presence of a pathogenic mutation in this region. Similar results were obtained for BB clones derived from 1873 and 1875, thus localizing a second inactivating mutation. The BK clones were all active. Fifteen out of eighteen clones from the mother's full-length cDNA were free of CBS activity; furthermore, all six BB clones expressed inactive CBS. Her NX and BK segments (6 clones each) were all active. These results indicated that the maternal mutation was located within the BB segment while the NX segment contained the paternal mutation.
Identification of mutations
We sequenced plasmids containing inactivating fragments to identify the mutations. Six inactive clones, containing full-length cDNA prepared from mother's (3009) mRNA were sequenced. The only change identified was a G715A transition in the BB segment (representative analysis: Fig. 2 ) substituting a positively charged lysine for a negatively charged glutamate at position 239 (E239K). In addition, the corresponding region of mother's genomic DNA was amplified, subcloned and sequenced to confirm her heterozygosity for the mutation. Half of these clones exhibited the mutation while the others were normal. These results are consistent with maternal heterozygosity. Three inactive BB clones derived from the affected siblings, 1873 and 1875, were sequenced. The same G715A transition (E239K) was found.
The inactive NX segments from 1873 and 1874 contained a pair of transversions, C233G and G^C (representative analysis: Fig. 3 ) which substituted arginine for proline at position 78 (P78R) and asparagine for lysine at position 102 (K102N); otherwise, the sequences of this segment were normal. Two NX segments from 1875, which had not been expressed, were also sequenced. The same pair was found in one of them, confirming the presence of the mutations in this patient as well.
These results strongly imply that the E239K mutation was inherited from the mother whereas the NX linked pair ( P78R and K102N) originated paternally.
Separation of the linked mutations by in vitro mutagenesis
Our results on the NX pair of mutations indicated that these mutations, expressed together, completely inactivated the enzyme. To determine the contribution of each mutation to the loss of CBS activity we next introduced each paternal mutation separately into expression plasmids by in vitro mutagenesis (9) ( Table 2) .
We expressed six in vitro mutagenized clones; three carried the P78R mutation, the other three carried the K102N mutation. Normal paternal NX segment from 1873 was used as control. Control CBS activities were slightly less than 400 U/mg protein. Expressed together, P78R and K102N completely inactivated CBS. Expressed separately, each reduced CBS activity by at least half (39-189 U/mg, P78R; 65-120 U/mg, K102N). The explanation for the variable mutant CBS activities is unclear, perhaps these subunits are relatively unstable in E. coli as observed before (10) .
Western blot CBS inactivity in vivo could result either from abundant, but catalytically defective, enzyme molecules or from complete absence of enzyme subunits (or both). To determine which of these possibilities might be responsible for the paucity of CBS in patient fibroblasts, we examined the intracellular CBS subunit content by Western blotting.
Fibroblasts. Fibroblast lysates from the three siblings (1873, 1874, 1875) and their mother (3009) were used for the analysis. Cell line extracts 1998 were used as control (Fig. 4, top panel) .
CBS subunits were virtually absent from fibroblast extracts taken from the homocystinuric siblings and their mother, consistent with the absence of CBS activity described above. Consequently, we conclude that the mutations described in this paper affect either reduced subunit synthesis or enhanced subunit degradation within the cell.
E.coli. The absence of CBS subunits in fibroblasts does not eliminate the possibility that any surviving subunits are also catalytically inactive. To investigate this possibility, we carried out similar analyses of E.coli cells expressing the mutations (Fig.  4, bottom panel) . In contrast to the total absence of detectable CBS in fibroblasts, CBS subunits were present in E.coli lysates from clones harboring either the two naturally occurring linked mutations (lane F), the maternal mutation (lane G), or each of the paternal mutations separated by in vitro mutagenesis (lanes B, C, D, E). Although CBS subunits were easily detectable, their amount was decreased compared to two controls (lanes A, H). Taken together with the corresponding CBS activity in these clones (Table 2) , we conclude that these patients expressed unstable CBS subunits which are functionally devoid of catalytic activity.
DISCUSSION
Whereas the maternal mutant allele contained a single, inactivating E239K mutation in the BB segment of the coding region, the paternal allele contained a pair of mutations (P78R, K102N), separated by 23 amino acids, located in the NX segment. Together, the paternal mutations completely inactivated the enzyme. When separated by in vitro mutagenesis, however, each of the mutations reduced the activity by about half. Another pair of mutations in the CBS coding region (R125Q, E131D) was previously reported (11) . Each of these, expressed separately, completely inactivated the enzyme. The origin of linked mutations is unclear. They could arise from independent events or from homologous recombination between a CBS allele and a pseudogene (11) . However, from our previous work there was no indication for the presence of a CBS pseudogene in the human genome (unpublished). The amino acid substitutions E239K, P78R and K102N change the enzyme sequence in regions which are highly conserved among species (12, 13) . This has been found to be the case for the majority of the CBS mutations reported so far (13) . Specifically, the E239K mutation changes a glutamate residue absolutely conserved from bacteria to humans (13) . P78 and K102, on the other hand, are present at these positions only in mammalian species. This lack of absolute conservation at these positions in lower species may explain our findings that each of the paternal mutations by itself only partially inactivated the enzyme. Neither the P78R nor the K102N mutation have been found separately to date; however, it is possible that both of these are phenotypically silent when unlinked.
In this report we showed that, even though their phenotypes exhibited considerable variability, the CBS genotypes of the three siblings were identical. Homocystinuria in both sisters was accompanied by many of the clinical signs of the classical phenotype, with some biological differences in presentation. Their homocystinuric brother, in contrast, was free of all physical abnormalities associated with CBS deficiency even though his plasma homocysteine levels were nearly tenfold greater than theirs. All three were B 6 -responsive; vitamin therapy eliminated homocysteine from the plasma. The absence of CBS subunits in extracts of cultured fibroblasts explains the failure of PLP to stimulate enzyme activity in vitro. These results underscore the limitations of enzyme assay as a predictor of vitamin responsiveness and disease severity in homocystinuric patients.
It is unclear how vitamin B 6 acts to reduce plasma homocysteine in these patients. Differential degradation in other tissues may spare sufficient CBS to account for this effect. Mutant forms of the enzyme are evidently degraded quickly in fibroblasts since CBS subunits are absent from these cells. The mutations do not inherently destabilize the proteins since mutant subunits are readily apparent in transformed bacteria. In bacteria, the mutant forms of the enzyme were catalytically inactive, however, the hosts were 'homozygous' for the mutation. In contrast, the patients were compound heterozygotes, and their CBS subunits might undergo Be-responsive complementation.
Alternatively, CBS activity depends upon the contributions of a number of pathways, including PLP (5), heme biosynthesis (14) and AdoMet formation (15) . Specifically, correct CBS folding evidently occurs only in the presence of heme (Kery and Kraus, unpublished) , and mutant enzyme subunits may be unusually dependent upon this agent. Accordingly, cells lacking appreciable amounts of heme, such as skin fibroblasts, may degrade improperly folded, mutant CBS subunits quite rapidly. Such factors may well be responsible for the biological variation of symptoms in these, and other, homocystinuric patients (6) .
Because the mother was predicted to only be an obligate heterozygote for CBS deficiency, the virtual absence of fibroblast CBS activity was unexpected. Our findings of 15 out of 18 inactive cDNA clones suggested that her fibroblasts contained more mutant than normal mRNA, perhaps accounting for the lack of CBS subunits in those cells. Examination of her genomic DNA clearly showed that one allele was normal while the other contained the G 7 i 5 A transition. She did not exhibit homocystinuria, therefore it is evident that other tissues express the normal allele.
Deletion of sequences within the test region of the expression cartridges was effective in eliminating false negative resultsthat is, expression of active enzyme derived from uncut or nicked parent plasmids. Screening of colonies by PCR was likewise simplified since recombinants contain larger patient inserts than do parental plasmids. Furthermore, the parental CBS alleles are separated in different E.coli clones and the three segments examined cover the entire coding region. Paternal and maternal alleles can be distinguished using polymorphic markers. The method readily discriminates between synonymous and pathogenic mutations because the latter inactivate the expressed enzyme while the former are without effect. Lastly, this procedure provides direct access to the mutant protein for further analysis. These advantages greatly facilitated this work.
MATERIALS AND METHODS
Expression plasmids
Expression cartridges were derived from pHCS3. This plasmid was prepared (6) by inserting normal human CBS cDNA into the bacterial expression vector, pkK388.1. The preparation of the expression plasmids for the mumrjonal screening is described in detail in Figure 1 .
cDNA preparations
Messenger RNA was isolated from a preparation of total fibroblast RNA (16) using Dynabeads (Dynal, Inc., Great Neck, NY) according to the manufacturer's conditions. Complementary DNA was synthesized from the mRNA preparation by extending the poly ddT primer using AMV RNA-dependent DNA polymerase (Life Sciences, Inc., St. Petersburg, FL) (17) .
Insert preparation
Test segments of cDNA were amplified by PCR, using Deep Vent (Pyrococcus; Psp) DNA polymerase (New England Biolabs, Beverly, MA) in lieu of Taq DNA polymerase to minimize PCR-generated artifacts. A detailed description of the development of this method has been described elsewhere (18) . Briefly, 100 /J of each reaction mixture (1 xDeep Vent buffer, supplied; dNTPs, 300 ^M each; sense and antisense primers, 80 pmols each; 3 mM MgSO 4 ; and 1 id cDNA) were denatured at 94°C for 4 min, then chilled quickly in an ice water slush. Following the addition of 1 U Psp polymerase, the mixtures were subjected to 30 thermal cycles in a Techne PHC-1 thermocycler: 94°C, 1 min; 55 °C, 1 min; 72°C, 1 min. Primers used for each segment were: Sense (183)5'-GAAGTTCGGCCTGAACTGTGAGC-3' Antisense (182)5'-GCTCACAGTTCAGGCCGAACTTC-3' Human CBS expression Transformed E.coli cells, containing the constructs, were grown to 0.5 ODJOO and CBS expression was induced for 1 h by the addition of UTG (0.33 mM final concentration). Cells were pelleted by centriftigation (3800 g, 5 min), washed and sonicated in 30 mM potassium phosphate buffer (pH 6.0) as described elsewhere (6) . Lysates were cleared of cell debris by centriftigation (14000 g, 15 min) in preparation for enzyme assay or Western blotting.
Enzyme assay and protein manipulations CBS assays in bacterial lysates (6) and fibroblast extracts (19) have been described previously. Western blots were performed on fibroblast extracts and bacterial lysates following SDS/PAGE on 9% gels (6).
Other methods
Hasmids from bacteria preparations were isolated using Magic Miniprep and Magic Maxiprep kits (Promega Biotech, Madison, WT). DNA sequences were determined by the CircumVent thermal cycle sequencing method (New England Biolabs, Beverly, MA) according to manufacturer's conditions.
